Literature DB >> 8149645

A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

N Fujimoto1, N Mouri, K Iwata, E Ohuchi, Y Okada, T Hayakawa.   

Abstract

A one-step sandwich enzyme immunoassay (EIA) for human matrix metalloproteinase 2 (MMP-2, 72-kDa gelatinase/type IV collagenase, EC 3.4.24.24) was established with a pair of monoclonal antibodies prepared against the precursor form of MMP-2 (proMMP-2) purified from the conditioned medium of human skin fibroblasts or against a synthetic peptide corresponding to the N-terminal domain of proMMP-2. ProMMP-2 in samples was allowed to simultaneously react with both solid-phase and peroxidase-labeled antibodies. Sensitivity of this EIA system was 2.4 pg/assay (0.24 microgram/l) and linearity was obtained between 10 and 5,000 pg/assay (1.0-500 micrograms/l). The EIA system recognized both the free form of proMMP-2 and its complex form with TIMP-2 with the same degree of immunoreactivity. ProMMP-2 levels in human sera from patients in various disease states were analyzed. In sera from patients with hyperthyroidism (12), primary biliary cirrhosis (8) and hepatocellular carcinoma (11), 749 +/- 166, 716 +/- 135 and 686 +/- 236 micrograms/l of proMMP-2 were detected, respectively and these were significantly higher than that observed in 213 normal human sera (570 +/- 118 micrograms/l). In contrast, the levels in sera from 33 patients with osteoarthritis (449 +/- 72 micrograms/l), 45 with rheumatoid arthritis (408 +/- 139 micrograms/l), 13 with stomach cancer (427 +/- 103 micrograms/l) and 10 with pancreatic cancer (422 +/- 130 micrograms/l) were significantly lower than that found in normal sera. Immunoblot and gel filtration analyses showed that human sera contain several MMP-2 species in addition to proMMP-2 which exist in a complex form with TIMP-2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8149645     DOI: 10.1016/0009-8981(93)90024-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  32 in total

1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon.

Authors:  M Arai; M Niioka; K Maruyama; N Wada; N Fujimoto; T Nomiyama; S Tanaka; I Okazaki
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

3.  Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage.

Authors:  K Imai; S Ohta; T Matsumoto; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

4.  Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.

Authors:  T Nakagawa; T Kubota; M Kabuto; N Fujimoto; Y Okada
Journal:  J Neurooncol       Date:  1996-04       Impact factor: 4.130

5.  Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.

Authors:  K M Walsh; P Timms; S Campbell; R N MacSween; A J Morris
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

6.  Aspirin suppresses TNF-α-induced MMP-9 expression via NF-κB and MAPK signaling pathways in RAW264.7 cells.

Authors:  Ping Zhang; Chao Wu; Xiao-Hui Huang; Chen-Lin Shen; Lin Li; Wei Zhang; Cheng-Zeng Yao
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

7.  Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Authors:  Naoko Sasaki; Yasuo Okumura; Ichiro Watanabe; Hiroaki Mano; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

8.  Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3.

Authors:  Takeyoshi Yokoyama; Hiroyuki Nakamura; Yoshihide Otani; Tetsuro Kubota; Noboru Fujimoto; Motoharu Seiki; Masaki Kitajima; Yasunori Okada
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis.

Authors:  K Ohashi; R Kawai; M Hara; Y Okada; S Tachibana; Y Ogura
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

10.  Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin.

Authors:  S Katsuda; Y Okada; Y Okada; K Imai; I Nakanishi
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.